Physician profile
Bradley Lander
NPI 1952759581
$2,421.73
in general payments reported to CMS, 2019-2025
20 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $388 · 2021: $457 · 2022: $642 · 2023: $38.67 · 2024: $197 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $688.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $568.10 | 2020-2022 | |
| Astellas Pharma US INC | $386.95 | 2021-2022 | |
| Philips North America LLC | $237.95 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $184.76 | 2019-2025 | Wainua |
| Pfizer INC. | $153.26 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $124.32 | 2020-2025 | Lifevest |
| Edwards Lifesciences Corporation | $123.14 | 2025 | Sapien 3 Ultra Resilia |
| E.R. Squibb & Sons, L.L.C. | $110.05 | 2024-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $93.80 | 2024-2025 | Onpattro |
| Novartis Pharmaceuticals Corporation | $64.18 | 2021-2022 | |
| Atricure, INC. | $61.30 | 2023-2025 | Synergy Ablation System |
| Takeda Pharmaceuticals U.S.A., INC. | $54.75 | 2024-2025 | Livtencity |
| Amgen INC. | $46.17 | 2022-2023 | Repatha |
| Esperion Therapeutics, INC. | $45.09 | 2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $34.25 | 2024 | Xarelto |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $33.32 | 2024-2025 | Watchman Flx |
| Sanofi-Aventis U.S. LLC | $31.34 | 2021-2024 | |
| Medtronic, INC. | $27.11 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.63 | 2021 | |
| Genzyme Corporation | $19.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Lander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.